is a privately-funded pharmaceutical company that was established in 2020 with a strong passion for growing high-quality, GMP-certified medical cannabis. Our company was founded on the vision of producing the best-quality medical cannabis and is driven by our investors’ commitment to providing patients with safe and effective treatments. As part of our commitment to quality and safety, Alphaplant has finalized the transfer of land and GMP license, and we are currently in the construction phase. We aim to complete the first infrastructure expansion of approximately 6500 sqm by Q4 – 2023, which will enable us to produce our first harvest of GMP-certified cannabis by the end of the same quarter. Our future plans are to extend our infrastructure facility to approximately 20.000 sqm, enabling us to produce a range of high-quality medical cannabis products to meet the needs of our customers. We aim to be a trusted brand for distributing the best quality of EU-GMP-certified medical cannabis to both local and international markets, providing patients with access to safe, effective, and affordable treatments. At Alphaplant, we are committed to staying at the forefront of the medical cannabis industry and providing our customers with the highest level of service and support. Our team of experts is dedicated to continuously improving our cultivation and production processes to deliver innovative, high-quality products that meet the needs of patients around the world.
From seed
to flower
The facility will host both mother plants and seedlings concurrently. This allows us to plan and cultivate multiple cultivars from seedling/ clone to final flower. Our facility and design allows for optimal cultivation.
GMP
Compliance
We will dry, analyse and process all cannabis following the best GMP practices in accordance of PICS standards. Our aim is to get EU-GMP accreditation by Q1 2024.
Expansible
Infrastructure
The greenhouse/ growing facility will be able to host up to 40,000 plants once phase 1 is done. Estimated harvest in year 1 will be up to 3 tonnes per annum which will increase to 5 tonnes when a full harvest cycle will be completed. Phase 2 expansion will increase total production up to 10 tonnes per annum.
We aim to be a trusted brand for providing best quality GMP-certified medicinal cannabis product which will be distributed to the local and advancing international markets. South Africa is positioned to be a global leader in the growing and producing of medical cannabis, more than 40 countries worldwide have approved the doctor prescribe use of medicinal cannabis. Globally the medicinal cannabis market was valued at US$20.4billion in 2017 and is expected to grow up to US$90.1billion in 2026. Alphaplant Pharmaceutical will invest into infrastructure located in Southern Africa which will position itself to produce the best quality GMP-certified medicinal cannabis products and grow to be a trusted brand locally and internationally.
We are also committed to educating the public and advocating for the use of medical cannabis as a safe and effective treatment option. We believe that by working together with patients, healthcare professionals, and the broader medical cannabis community, we can contribute to the ongoing progress in the field of medical cannabis research and improve the lives of those suffering from chronic conditions.
We are a company that places a strong emphasis on sustainability, efficiency, and environmental responsibility. Our cultivation process is designed to minimize waste, conserve resources, and reduce our environmental impact. We believe that by cultivating our products in an environmentally responsible manner, we can provide safe, effective, and sustainable medical cannabis products to our patients. In addition 80% of electricity consumption will be supplied from our on-site solar facility.
Copyright ©2023 Alphaplant Pharmaceutical (PTY) Ltd. All Rights Reserved. Regulated and monitored by the South African Health Products Regulatory Authority (SAHPRA) with license number: 0000000041MC Ð v2. For any questions please contact [email protected]
